Next Generation Lyme Diagnostics: Multi-Peptide Approach

Lyme Borreliosis, commonly known as Lyme disease, poses a significant health threat worldwide. The condition stems from infection by the bacterial species known as Borrelia, which is transmitted to humans through tick bites. Left untreated this condition can lead to severe health problems and long-term damage. Despite current tests serving as valuable diagnostic tools they still suffer from technical limitations, such as suboptimal sensitivity during the early stages of infection, variability in interpretation, and a propensity for false-positive results due to cross-reactivity with other antigens. Furthermore, existing tests still lack the capability to differentiate between past and active/chronic forms of the infection which can lead to further clinical complications. These limitations mainly stem from a single tests inability to capture the antigenic complexity of Borrelia species and patients’ heterogenous immune response to infection. This whitepaper introduces the “Epitogen Lyme Detect™ IgG test”, a peptide multiplex assay designed using 120 specific immunodominant peptides selected from 37 antigenic proteins covering the main pathogenic Borrelia species. This novel test demonstrates its significant potential in terms of sensitivity and specificity and thereby paves the way for the next generation of diagnostics based on peptide-precision.


Key Takeaways:

1) Current tests for Lyme disease have inherent limitations.

2) Comparative studies demonstrate the superior performance of the Epitogen® peptide-based test.

3) The Epitogen Lyme Detect™ IgG test is ready and available for evaluation and collaboration within the research community and its stakeholders.


Download the white paper:

 Next Generation Lyme Diagnostic